Related Experiment Videos
Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death
A Demartis1, F Bernassola, R Savino
1Istituto di Ricerche di Biologia Molecolare, P. Angeletti, Pomezia, Rome.
Abstract:
Interleukin-6 (IL-6) plays a central role in the pathogenesis of multiple myeloma, acting as both a growth and a survival factor for myeloma cells. A series of IL-6 receptor antagonists that are IL-6 variants has been recently obtained, the affinity of which for the ligand-specific receptor chain IL-6R alpha has been maintained or even increased, but the signaling of which is impaired by not being able to bind and/or dimerize the signaling chain gp130. Although IL-6 antagonists have been shown to inhibit the growth of IL-6-dependent myeloma, no information has been gathered on their ability to induce myeloma cell death. We show here that IL-6 receptor antagonists are pro-apoptotic factors for the IL-6-dependent human myeloma cell line XG-1. Their capacity to induce cell death is in direct relation to their affinity for IL-6R alpha, degree of gp130 binding impairment, and efficiency to inhibit intracellular signaling events. Interestingly, the most potent pro-apoptotic molecule, Sant7, counteracts the protective autocrine effect exercised by the limited amounts of IL-6 produced by XG-1 cells and is thus able to induce cell death at higher rate than just IL-6 deprivation. These findings are particularly relevant for the therapy of multiple myeloma.
Insights
Novel interleukin-6 (IL-6) receptor antagonists induce programmed cell death (apoptosis) in multiple myeloma cells. These IL-6 variants are potent pro-apoptotic factors, offering new therapeutic strategies for this cancer.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Interleukin-6 (IL-6) is crucial for multiple myeloma growth and survival.
- IL-6 receptor antagonists, designed as IL-6 variants, maintain IL-6R alpha affinity but impair gp130 signaling.
- Previous studies focused on growth inhibition, with limited data on apoptosis induction by these antagonists.
Purpose of the Study:
- To investigate the pro-apoptotic potential of IL-6 receptor antagonists in human myeloma cells.
- To correlate the apoptotic capacity with receptor binding and signaling inhibition.
- To evaluate the efficacy of the most potent antagonist, Sant7, against autocrine IL-6 effects.
Main Methods:
- Utilized IL-6 receptor antagonists as IL-6 variants with impaired gp130 dimerization.
- Tested these antagonists on the IL-6-dependent human myeloma cell line XG-1.
- Assessed cell death induction, receptor affinity, gp130 binding impairment, and signaling inhibition.
Main Results:
- IL-6 receptor antagonists demonstrated significant pro-apoptotic activity in XG-1 myeloma cells.
- Apoptosis induction correlated directly with IL-6R alpha affinity and gp130 binding impairment.
- The antagonist Sant7 effectively overcame autocrine IL-6 protection, inducing higher cell death rates than IL-6 deprivation alone.
Conclusions:
- IL-6 receptor antagonists are effective pro-apoptotic agents against IL-6-dependent multiple myeloma.
- The degree of gp130 signaling blockade is critical for their cytotoxic effect.
- These findings support the therapeutic potential of IL-6 receptor antagonists in multiple myeloma treatment.